- Info
- Insider Trading
- Financials
- Holders: LYEL, LYEL
Operating Margin of Lyell Immunopharma, Inc. from 31 Dec 2019 to 31 Dec 2025
- Taxonomy & unit
- ratio: %
- Description
- The operating margin measures the profit a company makes on a dollar of sales after accounting for the direct costs involved in earning those revenues.
- Summary
-
Lyell Immunopharma, Inc. quarterly and annual Operating Margin in % history and change rate from 31 Dec 2019 to 31 Dec 2025.
- Lyell Immunopharma, Inc. Operating Margin for the quarter ending 31 Dec 2025 was -748344%, a 27% decline year-over-year.
- Lyell Immunopharma, Inc. annual Operating Margin for 2025 was -748344%, a 27% decline from 2024.
- Lyell Immunopharma, Inc. annual Operating Margin for 2024 was -588123%, a 210% decline from 2023.
- Lyell Immunopharma, Inc. annual Operating Margin for 2023 was -190006%, a 14% increase from 2022.
Operating Margin, Quarterly (%)
Operating Margin, YoY Quarterly Change (%)
Operating Margin, Annual (%)
Operating Margin, YoY Annual Change (%)
Lyell Immunopharma, Inc. Quarterly Operating Margin (%)
| Period | Value | YoY Chg | Change % | Start Date | End Date |
|---|---|---|---|---|---|
| Q4 2025 | -748344% | -160221% | -27% | 01 Oct 2025 | 31 Dec 2025 |
| Q3 2025 | -836359% | -491730% | -143% | 01 Jul 2025 | 30 Sep 2025 |
| Q2 2025 | -593598% | -175728% | -42% | 01 Apr 2025 | 30 Jun 2025 |
| Q1 2025 | -554688% | -201707% | -57% | 01 Jan 2025 | 31 Mar 2025 |
| Q4 2024 | -588123% | -398117% | -210% | 01 Oct 2024 | 31 Dec 2024 |
| Q3 2024 | -344629% | -345189% | -61595% | 01 Jul 2024 | 30 Sep 2024 |
| Q2 2024 | -417870% | -418451% | -72077% | 01 Apr 2024 | 30 Jun 2024 |
| Q1 2024 | -352981% | -397868% | -886% | 01 Jan 2024 | 31 Mar 2024 |
| Q4 2023 | -190006% | +30886% | +14% | 01 Oct 2023 | 31 Dec 2023 |
| Q3 2023 | 560% | +1122% | 01 Jul 2023 | 30 Sep 2023 | |
| Q2 2023 | 581% | +1064% | 01 Apr 2023 | 30 Jun 2023 | |
| Q1 2023 | 44887% | +47490% | 01 Jan 2023 | 31 Mar 2023 | |
| Q4 2022 | -220892% | -218875% | -10853% | 01 Oct 2022 | 31 Dec 2022 |
| Q3 2022 | -562% | 01 Jul 2022 | 30 Sep 2022 | ||
| Q2 2022 | -484% | 01 Apr 2022 | 30 Jun 2022 | ||
| Q1 2022 | -2603% | 01 Jan 2022 | 31 Mar 2022 | ||
| Q4 2021 | -2017% | 01 Oct 2021 | 31 Dec 2021 |
Lyell Immunopharma, Inc. Annual Operating Margin (%)
| Period | Value | YoY Chg | Change % | Start Date | End Date |
|---|---|---|---|---|---|
| 2025 | -748344% | -160221% | -27% | 01 Jan 2025 | 31 Dec 2025 |
| 2024 | -588123% | -398117% | -210% | 01 Jan 2024 | 31 Dec 2024 |
| 2023 | -190006% | +30886% | +14% | 01 Jan 2023 | 31 Dec 2023 |
| 2022 | -220892% | -218875% | -10853% | 01 Jan 2022 | 31 Dec 2022 |
| 2021 | -2017% | +716% | +26% | 01 Jan 2021 | 31 Dec 2021 |
| 2020 | -2733% | +12806% | +82% | 01 Jan 2020 | 31 Dec 2020 |
| 2019 | -15539% | 01 Jan 2019 | 31 Dec 2019 |
* An asterisk sign (*) next to the value indicates that the value is likely invalid.